Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In
Big effect

Eczema incidence dropped from 67% to 26% in infants given a specific probiotic strain — but the result comes from a single Chinese trial that also saw fewer infections, leaving generalization uncertain.

This is the first indexed study on Bifidobacterium animalis subsp. lactis BLa80 for eczema, so while the effect size is striking, it needs replication before we can confidently say the benefit extends beyond this population and these co-measured outcomes.

In a randomized, double-blind trial of 180 Chinese infants (age 0–3), three months of daily Bifidobacterium animalis subsp. lactis BLa80 was linked to a 41-percentage-point lower rate of eczema over six months — 26% versus 67% in the placebo group. The probiotic also reduced upper respiratory infections and tracheitis, suggesting a broad immune effect. However, because this is the first major trial on this specific strain for these conditions, the findings are promising but not yet proven across different settings or populations.

Where this fits in the evidence

This is among the first studies we've indexed on Bifidobacterium bifidum Bb-02 for Reduced Eczema Incidence — treat it as an early signal until more research accumulates.

The study

Bifidobacterium animalis subsp. lactis BLa80 for preventing allergic, respiratory, and gastrointestinal diseases in young children in China: a randomized double-blind placebo-controlled trial.

  • Randomized Controlled Trial (RCT)
  • n = 180
  • 2026-02-15
  • Clinical and experimental pediatrics
More on Bifidobacterium bifidum Bb-02More on Reduced Eczema Incidence

This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.

Back to top